ANACOR ANNOUNCES RESULTS FROM ANTI-INFLAMMATORY TRIAL

A A

Anacor Pharmaceuticals has announced promising data from a Phase IIa study of AN0128, a novel topical anti-inflammatory drug candidate for atopic dermatitis (AD).

The multicenter, randomized, placebo-controlled study of AN0128, a novel topical anti-inflammatory drug candidate, enrolled 103 subjects with mild to moderate AD at eight centers. Study participants received twice daily treatment for four weeks with either AN0128 Cream 1 percent or vehicle cream. Efficacy was measured by a six-point (clear, almost clear, mild, moderate, severe, very severe) investigator static global assessment (ISGA) scale.